Molecular Factors in Carcinoma Ex Pleomorphic Adenoma: Systematic Review and Meta-Analysis

Seraphina Key; Clemente Chia; Zubair Hasan; Purnima Sundaresan; Faruque Riffat; Raghav C Dwivedi

doi:10.1002/lary.30993

Molecular Factors in Carcinoma Ex Pleomorphic Adenoma: Systematic Review and Meta-Analysis

Laryngoscope. 2024 Mar;134(3):1042-1053. doi: 10.1002/lary.30993. Epub 2023 Aug 23.

Authors

Seraphina Key^{1

2}, Clemente Chia^{2

3}, Zubair Hasan^{1

4

5}, Purnima Sundaresan^{1

6}, Faruque Riffat^{1

4

7}, Raghav C Dwivedi^{8

9

10}

Affiliations

¹ Faculty of Medicine and Health, University of Sydney, Westmead, New South Wales, Australia.
² St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
³ Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁴ Department of Otolaryngology - Head and Neck Surgery, Westmead Hospital, New South Wales, Westmead, New South Wales, Australia.
⁵ Department of Otolaryngology - Head and Neck Surgery, John Hunter Hospital, Sydney, New South Wales, Australia.
⁶ Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.
⁷ Macquarie University Hospital, Macquarie University, New South Wales, Australia.
⁸ Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.
⁹ Department of Otolaryngology - Head and Neck Surgery, University College London Hospitals NHS Foundation Trust, London, UK.
¹⁰ Division of Surgery and Interventional Science, University College London, London, UK.

PMID: 37610148
DOI: 10.1002/lary.30993

Abstract

Objective: Carcinoma ex pleomorphic adenoma (CXPA) is a rare malignant salivary gland tumor. Although multiple reviews have been published on salivary gland malignancies, it has been a decade since the last dedicated systematic review pertaining to CXPA alone was published. This study examines molecular factors in CXPA diagnosis.

Data sources: MEDLINE, CINAHL, Embase, Scopus, Web of Science (BIOSIS), Cochrane CENTRAL, Health Collection (Informit), OpenDOAR, and GreyNet International.

Review methods: Systematic review and meta-analysis from inception to October 31, 2022 for all English language studies pertaining to "carcinoma ex pleomorphic adenoma." Predicted incidence of each biomarker was calculated with meta-analysis. Comparison against pleomorphic adenoma (PA) and salivary duct carcinoma (SDC) when reported within the same study are performed. Risk of bias performed with JBI tool for prevalence studies.

Results: Of 19151 unique studies undergoing abstract screening, 55 studies (n = 1322 patients) underwent data analysis. Biomarkers with >3 studies were p53, HER2, AR, EGFR, PLAG1, ERBB, ER, PR, HMGA2, p16, p63, a-SMA, RAS, PTEN, PDL1, BRAF, PIK3CA, and c-kit. Highest incidence was seen in AR, EGFR, p16, and p53. Significant differences were demonstrated compared with PA and SDC. There was high heterogeneity and overall high risk of bias within studies.

Conclusion: Molecular factors are an area of interest in the diagnosis of CXPA. Our study results support examining CXPA as a discrete cohort in future targeted therapy trials. Laryngoscope, 134:1042-1053, 2024.

Keywords: biomarkers; carcinoma ex pleomorphic adenoma; humans; meta-analysis; molecular targeted therapy; pleomorphic adenoma; salivary gland cancer; salivary gland neoplasms.

Publication types

Meta-Analysis
Systematic Review
Review

MeSH terms

Adenocarcinoma*
Adenoma, Pleomorphic* / diagnosis
Biomarkers, Tumor
ErbB Receptors
Humans
Salivary Gland Neoplasms* / pathology
Tumor Suppressor Protein p53

Substances

Tumor Suppressor Protein p53
Biomarkers, Tumor
ErbB Receptors